Xuanzhu Bio-B Shares Surge Over 60% Following New Drug Approval and Inclusion in Stock Connect

Stock News03-19

Xuanzhu Bio-B (02575) saw its shares surge more than 60% during the trading session. As of the time of writing, the stock was up 27.21%, trading at HK$54.6, with a turnover of HK$122 million.

Recently, Xuanzhu Bio announced that its self-developed Class 1 innovative drug, piroxiclib tablets, received approval from the National Medical Products Administration for a new indication. The drug can now be used in combination with aromatase inhibitors (AI) as initial endocrine therapy for patients with HR+/HER2- advanced breast cancer.

This marks the third approved indication for piroxiclib in China, following earlier approvals for use in combination with fulvestrant and as a monotherapy. With this approval, piroxiclib has become the first and only drug of its kind in China to cover the entire treatment course for HR+/HER2- advanced breast cancer, including first-line, second-line, and later-line therapies.

On March 9, Xuanzhu Bio-B was included in the Hong Kong Stock Connect list. The company's share price rose sharply by 8.30% on that day, with a turnover of HK$48.3875 million, significantly higher than the year-to-date average daily turnover of HK$22.44 million, representing an increase of approximately 116%. The following day, the daily turnover further climbed to HK$61.9559 million, indicating strong interest from Stock Connect investors in positioning themselves early.

The rapid rebound in trading activity and early investor positioning in Xuanzhu Bio's secondary market performance is largely attributed to market recognition of the company's clear "innovation-to-commercialization" investment thesis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166422213?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 10:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166422213","market":"us","top_or_hot":-1,"title":"Xuanzhu Bio-B Shares Surge Over 60% Following New Drug Approval and Inclusion in Stock Connect","media":"Stock News","content":"<p>Xuanzhu Bio-B (02575) saw its shares surge more than 60% during the trading session. As of the time of writing, the stock was up 27.21%, trading at HK$54.6, with a turnover of HK$122 million.</p>\n<p>Recently, Xuanzhu Bio announced that its self-developed Class 1 innovative drug, piroxiclib tablets, received approval from the National Medical Products Administration for a new indication. The drug can now be used in combination with aromatase inhibitors (AI) as initial endocrine therapy for patients with HR+/HER2- advanced breast cancer.</p>\n<p>This marks the third approved indication for piroxiclib in China, following earlier approvals for use in combination with fulvestrant and as a monotherapy. With this approval, piroxiclib has become the first and only drug of its kind in China to cover the entire treatment course for HR+/HER2- advanced breast cancer, including first-line, second-line, and later-line therapies.</p>\n<p>On March 9, Xuanzhu Bio-B was included in the Hong Kong Stock Connect list. The company's share price rose sharply by 8.30% on that day, with a turnover of HK$48.3875 million, significantly higher than the year-to-date average daily turnover of HK$22.44 million, representing an increase of approximately 116%. The following day, the daily turnover further climbed to HK$61.9559 million, indicating strong interest from Stock Connect investors in positioning themselves early.</p>\n<p>The rapid rebound in trading activity and early investor positioning in Xuanzhu Bio's secondary market performance is largely attributed to market recognition of the company's clear \"innovation-to-commercialization\" investment thesis.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xuanzhu Bio-B Shares Surge Over 60% Following New Drug Approval and Inclusion in Stock Connect</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXuanzhu Bio-B Shares Surge Over 60% Following New Drug Approval and Inclusion in Stock Connect\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-19 10:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Xuanzhu Bio-B (02575) saw its shares surge more than 60% during the trading session. As of the time of writing, the stock was up 27.21%, trading at HK$54.6, with a turnover of HK$122 million.</p>\n<p>Recently, Xuanzhu Bio announced that its self-developed Class 1 innovative drug, piroxiclib tablets, received approval from the National Medical Products Administration for a new indication. The drug can now be used in combination with aromatase inhibitors (AI) as initial endocrine therapy for patients with HR+/HER2- advanced breast cancer.</p>\n<p>This marks the third approved indication for piroxiclib in China, following earlier approvals for use in combination with fulvestrant and as a monotherapy. With this approval, piroxiclib has become the first and only drug of its kind in China to cover the entire treatment course for HR+/HER2- advanced breast cancer, including first-line, second-line, and later-line therapies.</p>\n<p>On March 9, Xuanzhu Bio-B was included in the Hong Kong Stock Connect list. The company's share price rose sharply by 8.30% on that day, with a turnover of HK$48.3875 million, significantly higher than the year-to-date average daily turnover of HK$22.44 million, representing an increase of approximately 116%. The following day, the daily turnover further climbed to HK$61.9559 million, indicating strong interest from Stock Connect investors in positioning themselves early.</p>\n<p>The rapid rebound in trading activity and early investor positioning in Xuanzhu Bio's secondary market performance is largely attributed to market recognition of the company's clear \"innovation-to-commercialization\" investment thesis.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1166422213","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166422213","pubTimestamp":1773886841,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Xuanzhu Bio-B (02575) saw its shares surge more than 60% during the trading session. As of the time of writing, the stock was up 27.21%, trading at HK$54.6, with a turnover of HK$122 million....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard","BK1191":"制药","02575":"轩竹生物-B","BK4588":"碎股"},"translate_title":"新药获批并纳入沪股通后轩竹生物B股大涨超60%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"02575":1},"content_text":"Xuanzhu Bio-B (02575) saw its shares surge more than 60% during the trading session. As of the time of writing, the stock was up 27.21%, trading at HK$54.6, with a turnover of HK$122 million.\nRecently, Xuanzhu Bio announced that its self-developed Class 1 innovative drug, piroxiclib tablets, received approval from the National Medical Products Administration for a new indication. The drug can now be used in combination with aromatase inhibitors (AI) as initial endocrine therapy for patients with HR+/HER2- advanced breast cancer.\nThis marks the third approved indication for piroxiclib in China, following earlier approvals for use in combination with fulvestrant and as a monotherapy. With this approval, piroxiclib has become the first and only drug of its kind in China to cover the entire treatment course for HR+/HER2- advanced breast cancer, including first-line, second-line, and later-line therapies.\nOn March 9, Xuanzhu Bio-B was included in the Hong Kong Stock Connect list. The company's share price rose sharply by 8.30% on that day, with a turnover of HK$48.3875 million, significantly higher than the year-to-date average daily turnover of HK$22.44 million, representing an increase of approximately 116%. The following day, the daily turnover further climbed to HK$61.9559 million, indicating strong interest from Stock Connect investors in positioning themselves early.\nThe rapid rebound in trading activity and early investor positioning in Xuanzhu Bio's secondary market performance is largely attributed to market recognition of the company's clear \"innovation-to-commercialization\" investment thesis.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166422213","isCrawlerRequest":true}